CLRB - Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants | Benzinga
FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio.
Cellectar has secured four patents across the key global regions Europe, Australia and Canada, covering the company's proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform and lead drug in development, iopofosine I 131, including the following:
The European Patent Office (EPO) has granted patent application number 20172745.0, titled "Ether Phospholipid Compounds for Treating Cancer and Imaging Detection of Cancer Stem Cells". This patent significantly enhances the use of iopofosine I 131 for treating various cancers, including gliomas, lung cancer, melanoma, and more, with a focus on cancer stem cells. It also extends coverage for iopofosine I 131's application in underserved pediatric diseases, supporting upcoming clinical advancements.
The Canadian Intellectual Property Office (CIPO), the Australian Patent Office (IP Australia) and the EPO have granted patent number 17814042.2 for "Phospholipid Ether Analogs for the Identification and Isolation of Circulating Tumor Cells". This patent encompasses a method using cancer-targeted alkylphosphocholine analogs to effectively identify and isolate circulating tumor cells (CTCs) from various cancer types, providing a valuable diagnostic and research tool in the field of oncology. It underscores Cellectar's ability to target not only primary tumors but also elusive tumor cells in challenging locations, such as the bloodstream, and metastatic tissue which are often seeded by circulating tumor cells marking a significant advancement in developing targeted cancer treatments.
The IP Australia and the EPO have granted patent application number WO 2019199998 A1, titled "Fractionated Dosing Of A Phospholipid Ether Analog For The Treatment Of Cancer". This patent represents a significant ...